[Photo by Fusion Medical Animation on Unsplash]
The NIH recently announced that it has started enrolling adults for a Phase 2 clinical trial evaluating various additional COVID-19 booster shots.NIH’s National Institute of Allergy and Infectious Diseases (NIAID) is sponsoring the COVID-19 Variant Immunologic Landscape (COVAIL) trial.
“We are looking beyond the Omicron variant to determine the best strategy to protect against future variants,” NIAID Director Dr. Anthony S. Fauci said in a March 31 news release. “This trial will help us understand if we can use prototype and variant vaccines alone or together to shift immune responses to cover existing and emerging COVID-19 variants.”
The COVAIL trial will study immune responses induced by prototype vaccines and variant vaccine candidates — including bivalent vaccines, which target two SARS-CoV-2 variants. The goal is to inform future booste…